BioFunding

Pan-European stem cell project

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive €12m from the European Commission over the next five years. The key question the project will be trying to solve is how stem-cell reprogramming and differentiation is regulated at the epi­genetic level. In the spotlight are the polycomb repressive complex (PRC) and the nucleosome remodelling and histone deacetylase (NuRD) complexes, including the question of how they govern embryonic stem-cell differentiation in states of health and disease. The research is aimed at finding better ways of generating ethically unproblematic iPS cells, as well as opening up new pathways for directing the fate of stem cells into different specific tissue types. Headed by the CRG, the joint venture includes academic institutions from Great Britain, Denmark, the Netherlands, Belgium, Germany and Italy. Also on board are GlaxoSmith­Kline plc (UK) and three small biotechnology companies: Horizon Discovery Ltd. (UK), Cellartis AB (Sweden) and CLC bio (Denmark). Using its proprietary virally-mediated gene­engineering technology, Horizon is in charge of generating cell lines with labelled versions of epigenetic target proteins. Cellartis will provide human embryonic stem cells (hESCs), and is also involved in large-scale proteomic analyses. CLC bio will build the bio­informatics framework, while pharma giant GSK will assess the potential of translating fundamental scientific findings into new drugs.

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Displaying results 11 to 20 out of 1982

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/pan-european-stem-cell-project.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues